Ask about this productRelated genes to: FBXO8 antibody
- Gene:
- FBXO8 NIH gene
- Name:
- F-box protein 8
- Previous symbol:
- -
- Synonyms:
- FBX8, FBS
- Chromosome:
- 4q34.1
- Locus Type:
- gene with protein product
- Date approved:
- 2000-09-27
- Date modifiied:
- 2016-10-24
Related products to: FBXO8 antibody
Related articles to: FBXO8 antibody
- The microRNA-223 (miR-223)/FBXW7/FBXO8 molecular network governs ubiquitin-proteasome proteostasis, a cardinal process in cellular protein turnover. Dysregulation amplifies inflammatory cascades and expedites tissue degradation. This study elucidates stage-specific expression divergences of miRNAs-223 and its cognate F-box regulators in periodontitis. - Source: PubMed
Publication date: 2026/03/26
Bandi Dhathri PriyaSudhakar UmaRajamani Snophia RaniKrishnaswamy Balasubramanian - Acute lymphoblastic leukemia (ALL) is a hematological malignancy with high survival rates in children; however, certain high-risk subtypes pose significant challenges due to poor prognosis and frequent relapse. Ubiquitination, a post-translational modification critical for protein regulation, has been implicated in various cancer processes, yet its role in ALL remains poorly understood. - Source: PubMed
Publication date: 2025/05/01
Xian WeiChen YintingYu ShuiqingYe ZhitaoZhang YuYao Danlin - The F-box protein 8 Gene (FBXO8) has been shown to suppress invasion and metastasis in various cancer types. Recurrence and drug resistance pose significant challenges in renal cell carcinoma (RCC). Identifying novel biomarkers is crucial for addressing these issues. - Source: PubMed
Publication date: 2024/11/09
Luo ZhouanWu XiaopingXie JuanxiaTang HaoChen JingqiYe DongcaiDou ShangwenChen Songning - F-box only protein 8 (FBXO8) is a recently identified member of the F-box proteins, showcasing its novelty in this protein family. Extensive research has established FBXO8's role as a tumor suppressor in various cancers, including hepatocellular carcinoma, and colorectal cancer, Nevertheless, its functional, mechanistic, and prognostic roles in primary and metastatic breast cancer, particularly in different molecular subtypes of breast cancer, various stages, as well as its potential implications in immunotherapy, tumor microenvironment, and prognostic survival among breast cancer patients, remain unexplored. In this article, we employed a multi-dimensional investigation leveraging TCGA, TIMER, TISIDB, STRING, MEXPRESS, UALCAN, and cBioPortal databases to explore the underlying suppression mechanism of FBXO8 in breast cancer. FBXO8 negatively correlates with MYC, NOTCH, WNT and inflammatory signaling pathways in breast tumor microenvironment. Furthermore we conducted RT-PCR, western blot, cell proliferation, cell migration, and mRNA target gene RT-PCR analyses to elucidate the role of FBXO8 in breast cancer progression. Mechanistically, PTEN and FBXW7 expression were down-regulated and MYC, IL10, IL6, NOTCH1, WNT6 mRNA expressions were up-regulated in FBXO8 knockdown cell lines. c-MYC silenced cells showed an increase in FBXO8 protein level, which suggests a negative feedback loop between FBXO8 and c-MYC to control breast cancer metastasis. These findings illuminate the novel role of FBXO8 as a prognostic and therapeutic target across different molecular subtypes of breast cancer. Finally, through the utilization of virtual screening and Molecular Dynamics simulations, we successfully identified two FDA-approved medications, Ledipasvir and Paritaprevir, that demonstrated robust binding capabilities and interactions with FBXO8. - Source: PubMed
Publication date: 2024/01/30
Khan Abdul JamilMan ShadAbbas ManzarLiu ShihaoZhang Feng - Patients with colorectal cancer (CRC) often develop malignant regrowth of metastatic dormant tumor cells in liver years after primary treatment. FBX8 is involved in suppressing tumor metastasis. Short-term chemotherapy experiments and liver metastasis mice model of orthotopic injection into the cecum were performed to construct the dormant models. GST-pull-down assay, Co-IP and immunofluorescence were used to confirm the bindings among FBX8 and its substrates. FBX8 upregulated the expression of epithelial and stemness markers, while downregulated the expression of mesenchymal and proliferative markers associated with tumor cell dormancy. FBX8 promoted the maintenance of metastatic dormancy of CRC cells. Mechanistically, FBX8 directly bound to HIF-1α, CDK4 and C-myc through its Sec7 domain and led to the ubiquitin degradation of these proteins, thereby inhibiting cell cycle progression, proliferation, angiogenesis, and metastasis. Clinically, FBX8 expression was negatively correlated with the HIF-1α, CDK4, and c-Myc in CRC tissues. Our study reveals a novel mechanism of FBX8 in regulating tumor metastatic dormancy in liver and provides new strategies for the treatment of CRC metastasis. - Source: PubMed
Publication date: 2020/08/14
Zhu XiaohuiWang FeifeiWu XuehuiLi ZhouWang ZhizhiRen XiaoliZhou YangshuSong FuyaoLiang YunshiZeng ZhichengLiao WangjunDing YanqingLiao WentingLiang Li